MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: The Path to New Antibiotics

Back to infectious disease news Blogs list Cancer blog  


Subscribe To Infectious Disease News RSS Feed  RSS content feed What is RSS feed?

The Path to New Antibiotics




Scientists at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to a number of bacteria can be targeted to kill dangerous pathogens. In addition, researchers discovered chemical compounds that can inhibit this enzyme and suppress the growth of pathogenic bacteria. These findings are essential to develop new broad-spectrum antibacterial agents to overcome multidrug resistance. The research was reported in the Cell journal Chemistry & Biology on August 27.



The Path to New Antibiotics

Andrei Osterman, Ph.D., an associate professor in Burnham's Bioinformatics and Systems Biology program, and his colleagues, targeted the bacterial nicotinate mononucleotide adenylyltransferase (NadD), an essential enzyme for nicotinamide adenine dinculeotide (NAD) biosynthesis. NAD has a number of crucial functions in nearly all important pathogens and the bacterial NadD differs significantly from the human enzyme.

"It's clear that because of bacterial resistance, we need new, wide-spectrum antibiotics," said Dr. Osterman. "This enzyme is indispensable in a number of pathogens, so finding ways to inhibit it could give us new options against infection".

As per the National Institutes of Health, drug resistance is making a number of diseases increasingly difficult-and sometimes impossible-to treat. They point to tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA) as two pathogens that pose a serious threat to human health.

Using a structure-based approach, the team searched for low-molecular-weight compounds that would selectively inhibit bacterial NadD, but not the human equivalent, by screening, in silico, more than a million compounds. Experimental testing of the best predicted compounds against Escherichia coli and Bacillus anthracis (anthrax) led them to a handful of versatile inhibitory chemotypes, which they explored in detail. Using protein crystallography, a 3D structure of the enzyme in complex with one of the inhibitors was solved providing guidelines for further drug improvement.

"This is proof-of-concept that NadD is a good target to create antibacterial agents," said Dr Osterman. "This knowledge will be useful for both biodefense and public health. The next step is to find better inhibitors. We do not have a silver bullet yet, but we are certainly hitting a golden target."


Posted by: Mark    Source




Did you know?
Scientists at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to a number of bacteria can be targeted to kill dangerous pathogens. In addition, researchers discovered chemical compounds that can inhibit this enzyme and suppress the growth of pathogenic bacteria. These findings are essential to develop new broad-spectrum antibacterial agents to overcome multidrug resistance. The research was reported in the Cell journal Chemistry and Biology on August 27.

Medicineworld.org: The Path to New Antibiotics

SARS Main| SARS Abroad| SARS and Goverment| SARS Information in different languages| Media about SARS| Physicians resources for SARS| Reference information for SARS| Updates on SARS|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.